354 results
Primary: (part 3) Potential of BPR277 1% ointment b.i.d. to improve the clinical severity of lesional skin in the majority of NS patients at end of treatment versus baseline of >= 2 points, dose range and regimen relationship on clinical…
Primary objective: to evaluate the efficacy of subcutaneous application of methotrexate in patients with moderate to severe Psoriasis compared to Placebo as assessed by achieving the primary endpoint PASI 75 after a 16 week treatment phase.…
Primary Objective:The primary objectives of the study are to demonstrate:• Superiority of LAS41008 versus placebo based on the proportion of subjects achievingPASI 75 at week 16 (a 75% reduction in the Psoriasis Area and Severity Index, PASI,…
To evaluate the effectiveness, cost-effectiveness and quality of life of Flaminal® versus Flammazine® in the treatment of superficial and deep partial thickness burns.
To assess the efficacy and patient safety of (1)fractional laser treatment in combination with NB- UVB,(2) fractional laser treatment in combination with NB- UVB and topical corticosteroids versus NB-UVB treatment alone.
The objectification of the most effective surgical treatment, in which three operationprocedures are compared.
Primary objectives• To evaluate the systemic exposure of digoxin and furosemide after repeated topical CLS003 application in otherwise healthy subjects with multiple cutaneous warts;• To assess the safety/tolerability profile of CLS003.Secondary…
In this study the material of 6 donors is used to develop and validate a humanized psoriasis model in mice. Also, the team of TNO Triskelion will be trained.
Primary objective: • To assess efficacy of CLS003 in reduction of wart area after six weeks of treatment when applied to cutaneous warts (common or plantar)• To evaluate the activity of the ionic contra-viral therapy CLS003, in a HPV biomarker after…
The primary objective of this study is to assess the analgesic effect of fractional carbon dioxide laser assisted delivery of two topical anesthetics (articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) and eutectic mixture of…
We hypothesize that the long lasting therapeutic effect of coal tar could be mediated by effects on the skin microbiome and/or effects on cellular memory by epigenetic changes. In atopic dermatitis patients, coal tar therapy could modify the skin…
To objectify skin barrier repair characteristics of coal tar in atopic dermatitis patients, by quantifying changes in NMF, lipid levels, TEWL, SCORAD-score and cytokine levels
Evaluate long-term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa.
By means of this in vivo study, we try to non-invasively get insights into the pharmacokinetics of PPD applied to the human skin. By studying penetration rate, penetration depth, allocation to different skin departments (stratum corneum, epidermis,…
The primary objectives are:- To demonstrate the relationship of blood flow in the hands and the extent of digital ulcera in patients with systemic scleroderma;- Evaluate the effect of bosentan on the blood flow in the hands from baseline to 12 weeks…
Correcting the causative factors of intertrigo is critical. Take steps to eliminate friction, heat, and maceration by keeping folds cool and dry. The goals of pharmacotherapy for intertrigo are to reduce morbidity and to prevent complications. To…
Primary Objective:* To determine the efficacy of silver impregnated dressings compared to a topical antibiotic to treat patients with PEG-site infections.Secondary Objectives:* To investigate the reduction and or change in stomal bacterial profile…
See above
Primary Objectives-To compare the efficacy responses of CP-690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP-690,550 treatment and subsequent withdrawal of active treatment at various timepoints during the 16-week double-blind…
- To determine the response based on Palmo-plantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at the end of treatment (week 24), or at the latest assessment for patients who withdraw prematurely